CATEGORY

Gene Therapy Trials

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Gene Therapy Trials.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Category Alerts


CATEGORY ALERTS

Charles River Receives EMA Approval to Produce Allogeneic Cell Therapy

August 11, 2022
alert level: Medium
CATEGORY ALERTS

Porton Advanced and Royaltech Form Collaboration

September 06, 2022
alert level: Medium

Become a Beroe LiVE.Ai™ Subscriber to receive proactive alerts on Gene Therapy Trials

Gene Therapy Trials Market Monitoring Dashboard


Supply Demand

Understand the correlation between costs, margins, and prices impacting your category on a real time basis on Beroe LiVE.Ai™

Gene Therapy Trials Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in Gene Therapy Trials category is 5.40%

Payment Terms

(in days)

The industry average payment terms in Gene Therapy Trials category for the current quarter is 73.4 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Gene Therapy Trials Suppliers


    1,202
    Total Suppliers
    42
    Diverse Suppliers
    67
    Normalized Supplier Rating
    Gene Therapy Trials Supplier

    Find the right-fit gene therapy trials supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Gene Therapy Trials market report transcript


    Gene Therapy Trials Global Market Outlook:

    Market Growth:

    The global gene therapy market was estimated at $1.40 billion in 2020, and it is expected to grow at a CAGR of 15–16 percent to reach $3 billion by 2025

    Demand Drivers
    • Increase in the number of active or recruiting trials is expected to increase the demand for gene therapy manufacturing services
    • The limited treatment options available for rare diseases and the need for lifelong medications are further propelling the growth of the gene therapy market

    Market Overview

    The gene therapy market is growing and collaborations among biotech players have increased, due to increase in number of approvals for gene therapy clinical trials. These therapies are also being accepted largely by physicians as well as patients
    • Oncology and monogenic diseases contribute majorly to the overall market share. Viral vector is more preferred over non-viral vectors in gene therapies, because of the various benefits, like high efficiency of gene transduction, specific gene targeting and delivery, safety
    • Even though the market is growing, a few hiccups in the gene therapy market are safety and efficacy related, prolonged lab procedures for trial studies, lack of knowledge of product interaction with the host, and the most importantly, the high cost of gene therapy products
    • The UK is establishing itself as a hub for cell and gene therapies and contributes to almost 12 percent of all the global clinical trials, its Y-o-Y no. of trials have also doubled. The studies conducted are majorly backed up by international companies, leading them to reach recru itment phase at a faster rate

    Insights On Gene Therapy CRO Landscape

    Service landscape for gene therapy in rare disease is a fragmented market, wherein the top CRO and niche CRO hold an average experience of conduction on 30
    studies
    • Supplier selection can be done on case-by-case basis with regards to gene therapy modalities and global trial landscape
    • Sponsors prefer engagement with mid-sized CRO, with a niche therapeutic focus given their lean management structure and flexibility
    • Long-term collaborations are currently forming the basis of gene therapy engagement

    Case Study: A mid-sized pharma company wanted to launch a vaccine using adenovirus vectors. During supplier selection, they took into consideration the platform
    expertise, in terms of the kind of partners they had for adenovirus vaccine delivery. Finally, two CROs (one from USA and other vendor from Europe) were selected
    on a regional basis and engaged on a project-based model.